Nicox S.A., a prominent player in the health care biotechnology sector, continues to make strides in its mission to develop innovative therapies for ophthalmic conditions. Headquartered in Valbonne, France, Nicox has established itself as a key entity in the biotechnology landscape, focusing on both national and international markets. The company’s dedication to advancing eye care is evident through its diverse product pipeline, which includes several promising candidates and formulations.
Among its notable products is Vyzulta™, an intraocular pressure-lowering treatment designed to address critical needs in glaucoma management. Additionally, Nicox is advancing NCX 470, a nitric oxide (NO)-donating candidate, which holds potential for treating glaucoma through novel mechanisms. The company’s portfolio also features stand-alone NO donors tailored for specific ophthalmic applications, showcasing its commitment to innovation in eye care.
ZERVIATE, another significant offering, is an eye drop formulation of cetirizine aimed at alleviating symptoms of allergic conjunctivitis. Furthermore, Nicox is developing NCX 4280, an ophthalmic solution targeting morning ocular congestion, and NCX 4251, a patented formulation of fluticasone propionate designed to treat blepharitis. These products highlight Nicox’s strategic focus on addressing a wide range of ophthalmic conditions.
Nicox’s collaborative efforts with industry giants such as Bausch + Lomb, AstraZeneca, Merck, Pfizer, and Ironwood Pharmaceuticals, Inc., as well as Novaliq GmbH, underscore its strategic partnerships aimed at enhancing its research and development capabilities. These collaborations are pivotal in driving forward the company’s innovative pipeline and expanding its therapeutic reach.
As of the latest update, Nicox reported no new developments beyond the completion of a new drug application, with key data generation scheduled for submission in the first half of 2026. The company’s stock performance reflects a moderate trading level, with the latest close at €0.30. This price is positioned midway between its 52-week high of €0.65 and its 52-week low of €0.20, indicating a 53% increase from the one-year low and a 54% decrease from the one-year high. The €0.45 spread over the past year suggests modest volatility, with a 75% range relative to the current price.
With a market capitalization of €21,240,286, Nicox continues to navigate the biotechnology sector with a focus on delivering impactful ophthalmic solutions. Founded in 1996, the company remains committed to its mission of improving eye health through cutting-edge research and development. For more information, stakeholders and interested parties can visit Nicox’s website at www.nicox.com , where they are listed on both the NYSE and Euronext Paris stock exchanges.